T Wen1, C Su1, X Cheng1, Y Wang1, T Ma1, Z Bai1, H Zhang2, Z Liu3. 1. No. 2 Department of Thoracic Surgery, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, China. 2. Department of Central Laboratory, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, China. 3. No. 2 Department of Thoracic Surgery, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, China. LZD20211101@163.COM.
Abstract
PURPOSE: Myeloid-derived suppressors cells (MDSCs) are heterogeneous immunosuppressive cells, closely related to the development, efficacy and prognosis in various tumors. The relationship between clinicopathological characteristics, efficacy of neoadjuvant chemoimmunotherapy (NCIO) and circulating MDSCs in patients with non-small cell lung cancer (NSCLC) was investigated in this study. METHODS: This study analyzed the clinical data of patients diagnosed at Department of Thoracic Surgery, Beijing Chest Hospital from November 2020 to August 2021. MDSCs and T cells subgroups were measured in fresh peripheral blood mononuclear cells(PBMCs) at baseline. Flow cytometry was used to detect MDSCs and T cells subgroups. RESULTS: A total of 78 patients with NSCLC and 20 patients with benign nodule underwent direct surgery. 23 patients with NSCLC scheduled to accept NCIO before surgery. NSCLC had elevated levels of total MDSCs, PMN-MDSCs and M-MDSCs compared to patients with benign nodule. MDSCs subgroups were correlated to the pTNM stage in NSCLC patients. The frequency of total MDSCs were moderately positively correlated with regulatory T cells (Tregs)(r = 0.3597, P < 0.01) and negatively correlated with CD4 + T cells(r = 0.2714, P < 0.05). The baseline levels of total MDSCs, PMN-MDSCs and Tregs in pCR patients were significantly decreased than those of non-pCR patients (P < 0.05). CONCLUSION: Circulating MDSCs were increased in NSCLC patients. MDSC subgroups were related to pTNM stage in NSCLC patients. Total MDSCs were positively correlated with Tregs levels and negatively correlated with CD4 + T cells in peripheral blood. The level of MDSCs and Tregs in peripheral blood may have potential value in predicting pathological response in NSCLC.
PURPOSE: Myeloid-derived suppressors cells (MDSCs) are heterogeneous immunosuppressive cells, closely related to the development, efficacy and prognosis in various tumors. The relationship between clinicopathological characteristics, efficacy of neoadjuvant chemoimmunotherapy (NCIO) and circulating MDSCs in patients with non-small cell lung cancer (NSCLC) was investigated in this study. METHODS: This study analyzed the clinical data of patients diagnosed at Department of Thoracic Surgery, Beijing Chest Hospital from November 2020 to August 2021. MDSCs and T cells subgroups were measured in fresh peripheral blood mononuclear cells(PBMCs) at baseline. Flow cytometry was used to detect MDSCs and T cells subgroups. RESULTS: A total of 78 patients with NSCLC and 20 patients with benign nodule underwent direct surgery. 23 patients with NSCLC scheduled to accept NCIO before surgery. NSCLC had elevated levels of total MDSCs, PMN-MDSCs and M-MDSCs compared to patients with benign nodule. MDSCs subgroups were correlated to the pTNM stage in NSCLC patients. The frequency of total MDSCs were moderately positively correlated with regulatory T cells (Tregs)(r = 0.3597, P < 0.01) and negatively correlated with CD4 + T cells(r = 0.2714, P < 0.05). The baseline levels of total MDSCs, PMN-MDSCs and Tregs in pCR patients were significantly decreased than those of non-pCR patients (P < 0.05). CONCLUSION: Circulating MDSCs were increased in NSCLC patients. MDSC subgroups were related to pTNM stage in NSCLC patients. Total MDSCs were positively correlated with Tregs levels and negatively correlated with CD4 + T cells in peripheral blood. The level of MDSCs and Tregs in peripheral blood may have potential value in predicting pathological response in NSCLC.
Authors: Alexander Martens; Kilian Wistuba-Hamprecht; Marnix Geukes Foppen; Jianda Yuan; Michael A Postow; Phillip Wong; Emanuela Romano; Amir Khammari; Brigitte Dreno; Mariaelena Capone; Paolo A Ascierto; Anna Maria Di Giacomo; Michele Maio; Bastian Schilling; Antje Sucker; Dirk Schadendorf; Jessica C Hassel; Thomas K Eigentler; Peter Martus; Jedd D Wolchok; Christian Blank; Graham Pawelec; Claus Garbe; Benjamin Weide Journal: Clin Cancer Res Date: 2016-01-19 Impact factor: 12.531
Authors: Jing Liu; Stephen J Blake; Michelle C R Yong; Heidi Harjunpää; Shin Foong Ngiow; Kazuyoshi Takeda; Arabella Young; Jake S O'Donnell; Stacey Allen; Mark J Smyth; Michele W L Teng Journal: Cancer Discov Date: 2016-09-23 Impact factor: 39.397
Authors: Moshe C Ornstein; Claudia Marcela Diaz-Montero; Patricia Rayman; Paul Elson; Samuel Haywood; James H Finke; Jin S Kim; Paul G Pavicic; Marcelo Lamenza; Sarah Devonshire; Priscilla Dann; Kim Schach; Andrew Stephenson; Steven Campbell; Hamid Emamekhoo; Marc S Ernstoff; Christopher J Hoimes; Timothy D Gilligan; Brian I Rini; Jorge A Garcia; Petros Grivas Journal: Urol Oncol Date: 2018-03-30 Impact factor: 3.498
Authors: Yago Pico de Coaña; Maria Wolodarski; Irene van der Haar Àvila; Takahiro Nakajima; Stamatina Rentouli; Andreas Lundqvist; Giuseppe Masucci; Johan Hansson; Rolf Kiessling Journal: Oncoimmunology Date: 2020-08-28 Impact factor: 8.110